Biocardia Stock Today

BCDA Stock  USD 2.60  0.03  1.17%   

Performance

Modest

 
Weak
 
Strong

Odds Of Distress

High

 
High
 
Low
Biocardia is trading at 2.60 as of the 16th of March 2025, a 1.17 percent increase since the beginning of the trading day. The stock's open price was 2.57. Biocardia has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
14th of March 2008
Category
Healthcare
Classification
Health Care
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart and Morph deflectable guides and sheaths. The company has 4.58 M outstanding shares of which 56.22 K shares are currently shorted by private and institutional investors with about 0.45 trading days to cover. More on Biocardia

Moving against Biocardia Stock

  0.59ENVB Enveric Biosciences Earnings Call Next WeekPairCorr
  0.55MRK Merck Company Sell-off TrendPairCorr
  0.52MOLN Molecular PartnersPairCorr
  0.51MLTX MoonLake ImmunotherapeutiPairCorr
  0.5PALI Palisade BioPairCorr
  0.5PEPG PepGenPairCorr

Biocardia Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEOPeter Altman
Thematic IdeaBiotech (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Biotech, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.170.18
Notably Down
Slightly volatile
Total Current Liabilities4.4 M4.1 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total630.9 K1.1 M
Way Down
Slightly volatile
Total Assets3.3 M3.4 M
Notably Down
Pretty Stable
Total Current Assets1.6 M1.7 M
Notably Down
Slightly volatile
Debt Levels
Biocardia can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Biocardia's financial leverage. It provides some insight into what part of Biocardia's total assets is financed by creditors.
Liquidity
Biocardia currently holds 1.31 M in liabilities with Debt to Equity (D/E) ratio of 0.26, which may suggest the company is not taking enough advantage from borrowing. Biocardia has a current ratio of 2.94, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Biocardia's use of debt, we should always consider it together with its cash and equity.

Change In Cash

(5.35 Million)
Biocardia (BCDA) is traded on NASDAQ Exchange in USA. It is located in 320 Soquel Way, Sunnyvale, CA, United States, 94085 and employs 16 people. Biocardia is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 11.92 M. Biocardia conducts business under Biotechnology sector and is part of Health Care industry. The entity has 4.58 M outstanding shares of which 56.22 K shares are currently shorted by private and institutional investors with about 0.45 trading days to cover. Biocardia currently holds about 8.61 M in cash with (9.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.49.
Check Biocardia Probability Of Bankruptcy
Ownership Allocation
The market capitalization of Biocardia is $11.92 Million. Biocardia retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Biocardia Ownership Details

Biocardia Stock Institutional Holders

InstituionRecorded OnShares
Advisor Group Holdings, Inc.2024-12-31
61.0
Sbi Securities Co Ltd2024-12-31
15.0
Northern Trust Investments N A2024-12-31
0.0
Susquehanna International Group, Llp2024-12-31
43.8 K
Geode Capital Management, Llc2024-12-31
31 K
Cm Management, Llc2024-12-31
25 K
Vanguard Group Inc2024-12-31
12.9 K
Ubs Group Ag2024-12-31
4.8 K
Morgan Stanley - Brokerage Accounts2024-12-31
K
Pingora Partners Llc2024-12-31
K
Jpmorgan Chase & Co2024-12-31
899
View Biocardia Diagnostics

Biocardia Historical Income Statement

At present, Biocardia's Other Operating Expenses is projected to increase significantly based on the last few years of reporting. The current year's Cost Of Revenue is expected to grow to about 9.3 M, whereas Depreciation And Amortization is forecasted to decline to about 91.8 K. View More Fundamentals

Biocardia Stock Against Markets

Biocardia Corporate Management

Edward GillisSenior DevicesProfile
Ian McNieceChief OfficerProfile
Sujith ShettyChief RegulatoryProfile
Sujith MBBSChief RegulatoryProfile
When determining whether Biocardia offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biocardia's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biocardia Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biocardia Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biocardia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocardia. If investors know Biocardia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biocardia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.03)
Revenue Per Share
0.036
Quarterly Revenue Growth
(0.93)
Return On Assets
(0.97)
Return On Equity
(7.38)
The market value of Biocardia is measured differently than its book value, which is the value of Biocardia that is recorded on the company's balance sheet. Investors also form their own opinion of Biocardia's value that differs from its market value or its book value, called intrinsic value, which is Biocardia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biocardia's market value can be influenced by many factors that don't directly affect Biocardia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biocardia's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biocardia is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biocardia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.